ECL:NYSEEcolab Inc. Analysis
Data as of 2026-03-10 - not real-time
$281.86
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Ecolab (ECL) is trading at $281.86, which sits below its 20‑day ($299.47) and 50‑day ($285.20) simple moving averages but remains above the 200‑day SMA ($272.62), suggesting short‑term pressure within a longer‑term uptrend. The 14‑day RSI of 35.5 points to near‑oversold conditions, while the MACD shows a bearish histogram (-3.65) and a signal line that is higher than the MACD line, hinting at potential downside momentum. Nevertheless, the computed trend direction is bullish and the price is comfortably above the identified support level of $274.76, offering a technical cushion. Volatility over the past 30 days is elevated at roughly 21.5%, but the beta of 0.56 indicates lower systematic risk relative to the market. On the fundamentals side, Ecolab posted $16.1 B in revenue with a robust 17.8% growth rate, expanding margins (gross 44.5%, operating 14.7%) and an EPS beat in Q4 2025 ($2.08 vs $2.06 estimate). The company’s dividend yield of 0.98% is supported by a modest payout ratio of 37% and strong free cash flow, while analysts (21 in total) maintain a “buy” consensus with a median target price of $327, implying roughly 16% upside despite a DCF fair value of $147.76 that flags valuation concerns.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price above support but below short‑term SMAs
- RSI near oversold and MACD bearish signal
- Stable volume and low beta limiting market‑wide swings
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue and EPS growth with margin expansion
- Analyst consensus buy and target median price above current level
- Sustainable dividend and solid free cash flow
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Long‑term demand for water, hygiene, and infection‑prevention solutions
- Resilient global footprint across multiple high‑growth industries
- Competitive moat reinforced by brand portfolio and recurring service contracts
Key Metrics & Analysis
Financial Health
Revenue Growth17.80%
Profit Margin12.91%
P/E Ratio38.7
ROE22.52%
ROA7.84%
Debt/Equity103.92
P/B Ratio12.0
Op. Cash Flow$3.0B
Free Cash Flow$1.6B
Technical Analysis
TrendBullish
RSI35.5
Support$274.76
Resistance$309.27
MA 20$299.47
MA 50$285.20
MA 200$272.62
MACDBearish
VolumeStable
Fear & Greed Index75.89
Valuation
Fair Value$147.76
Target Price$321.86
Upside/Downside14.19%
GradeOvervalued
TypeGrowth
Dividend Yield0.98%
Risk Assessment
Beta0.56
Volatility21.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.